Company intelligence / Profile preview

Cellular Engineering Technologies

Coralville, Iowa, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Cellular Engineering Technologies does not develop therapeutics clinically; they develop and supply cell lines, iPSC reprogramming kits, and yeast-expressed human proteins as research tools to enable discovery and development of next-generation cell and regenerative therapies[3][5].

Therapeutic areas: OncologyOtherDermatologyImmunology
Modalities: Induced pluripotent stem cell derived therapyProteinRecombinant proteinEngineered yeast-based protein production
Industry: Non-Drug Biotech

Partnerships

ERS Genomics (CRISPR/Cas9 IP license)

Beyond the preview

Go deeper on Cellular Engineering Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular Engineering Technologies.

Explore the full profile